本公司及董事会全体成员保证公告内容真实、准确和完整， 并对公告中的虚假记载、误导性陈述或者重大遗漏承担连带责任。 证券代码：002432 证券简称：九安医疗 公告编号：2024-058 天津九安医疗电子股份有限公司 关于回购公司股份的进展公告 2、公司未在下列交易时间进行回购股份的委托： 天津九安医疗电子股份有限公司（以下简称"公司"）于 2024 年 2 月 5 日 召开第六届董事会第十次会议，逐项审议并通过了《关于公司回购股份方案的议 案》，同意公司拟以自有资金不低于 6 亿元人民币（含）且不超过 12 亿元人民 币（含）且回购价格不超过人民币 45 元/股（含）回购公司股份。本次回购股份 用于维护公司价值及股东权益和减少注册资本，其中用于维护公司价值及股东权 益而出售的股份回购的资金总额不高于 3.65 亿元，实施期限为自公司董事会审 议通过最终回购股份方案之日起不超过 3 个月；用于减少注册资本而注销的股份 回购的资金总额不低于 2.35 亿元，实施期限为自公司股东大会审议通过回购方 案之日起不超过 12 个月。具体回购数量以回购期限届满时实际回购的股份数量 为准。此外，因公司实施 2023 年年度权 ...

Group 1: Company Overview and Strategic Focus - The company is focused on promoting the "O+O" (Offline+Online) model for diabetes care in both China and the United States, aiming to establish a strong market presence and brand recognition [4][14]. - The iHealth brand has gained significant recognition in the U.S. market, with plans to leverage this to introduce more competitive products [14][16]. - The company has a clear strategy to enhance its product offerings in the home medical electronics and IVD (in vitro diagnostics) sectors [14][16]. Group 2: Financial Performance and Market Position - As of the end of July 2024, the company had approximately 82,700 shareholders, reflecting a stable investor base [5]. - The revenue from diabetes care services reached approximately 31.73 million yuan in the first half of 2024, with over 240,000 patients receiving care under the new model [10][12]. - The gross profit margin for iHealth products was reported at 76.52% for the first half of 2024, an increase from 68.82% in the same period last year [15]. Group 3: Product Development and Market Demand - The continuous glucose monitoring system (CGMS) is currently in the preclinical stage, with plans for clinical testing and FDA registration [14][16]. - The company has seen strong sales performance for its iHealth products, with revenues of approximately 1.195 billion yuan in the first half of 2024, primarily driven by COVID-19 testing kits [5][10]. - The iHealth three-in-one testing product has received FDA emergency use authorization and is actively being marketed through online and offline channels [9][15]. Group 4: Investor Relations and Market Strategy - The company has conducted stock buybacks amounting to nearly 2.2 billion yuan from 2023 to 2024, demonstrating commitment to maintaining shareholder value [13][15]. - The management emphasizes the importance of adapting strategies to local market conditions, particularly in the U.S. and China, to enhance competitive advantages [12][14]. - The company is exploring partnerships with AI startups to improve chronic disease management efficiency and reduce operational costs [16].

| 其他关联 | | 往来方与上市 | 上市公司核算 | 2024 年期初 | 2024 年 1-6 月 2024 年 1-6 月 | 2024 年 1-6 月偿 | 2024 | 年 6 月末 往来形成原 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 资金往来 | 资金往来方名称 | 公司的关联关 | 的会计科目 | 往来资金余额 | 往来累计发生额 往来资金的利息 | 还累计发生金额 | | 往来资金余额 因 | 往来性质 | | | | 系 | | | （不含利息） | | | | | | | 北京爱和健康科技服务有限公司 | 全资子公司 | 其他应收款 | 3,336.56 | 992.50 | - | | 4,329.06 代垫费用 | 经营性往来 | | | 北京爱和健康科技有限公司 | 控股子公司 | 其他应收款 | 2,685.63 | 60.00 | 2,745.63 | | - 代垫费用 | 经营性往来 | | | iHealthLabs Europe | 控股子公司 | 其他应收款 | 440.96 ...

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 1,350,913,448.99, a decrease of 40.82% compared to CNY 2,282,752,911.68 in the same period last year[12]. - Net profit attributable to shareholders was CNY 601,759,508.44, down 23.42% from CNY 785,816,244.18 in the previous year[12]. - The net profit after deducting non-recurring gains and losses increased by 42.36% to CNY 697,546,215.37 from CNY 489,995,219.80 in the same period last year[12]. - The net cash flow from operating activities was CNY 364,776,483.01, a significant decline of 77.75% compared to CNY 1,639,321,130.69 in the previous year[12]. - Basic earnings per share decreased by 17.36% to CNY 1.3788 from CNY 1.6685 in the same period last year[12]. - The company reported a net profit of approximately 309.19 million CNY for its subsidiary iHealth Inc., which focuses on software technology development and product sales[70]. - The company reported a net loss of approximately 88.68 million yuan for the current period, indicating a significant financial challenge[154]. - The total comprehensive income for the first half of 2024 was CNY 9,748,401.57, significantly lower than CNY 56,761,346.90 in the first half of 2023[148]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 23,948,227,624.84, an increase of 5.88% from CNY 22,619,116,790.11 at the end of the previous year[12]. - Net assets attributable to shareholders decreased by 2.42% to CNY 18,764,149,039.67 from CNY 19,229,372,817.81 at the end of the previous year[12]. - The company's total liabilities increased significantly to CNY 3,329,634,712.42 from CNY 1,610,070,968.85, a rise of 106.5%[143]. - The company's equity attributable to shareholders decreased from CNY 19,229,372,817.81 to CNY 18,764,149,039.67, a decline of approximately 2.4%[140]. - The company's total current liabilities increased from CNY 1,517,210,322.49 to CNY 1,706,312,564.37, reflecting a growth of about 12.5%[140]. Investment and R&D - The company is focusing on the development of new products and technologies, including the iHealth series products and IVD products[5]. - Research and development investment was ¥122,356,449.90, down 21.44% from ¥155,757,474.21 in the previous year[48]. - The company has established multiple research and development labs to enhance technology innovation and product lines in health management[21]. - The company has invested $30 million in a domestic AI language model startup, indicating a strategic focus on technology innovation[27]. - The CGMS project is a core strategic initiative, with resources being concentrated to accelerate its development and implementation[31]. Market Strategy and Expansion - The company plans to promote its diabetes care "O+O" model in China and the United States as part of its core strategy[5]. - The company plans to leverage its brand advantage in the U.S. market to introduce competitive technologies and products[23]. - The company is expanding its diabetes care model to approximately 320 hospitals across 50 cities in China, with a patient scale exceeding 240,000[24]. - The company aims to expand its diabetes care "O+O" model, integrating online and offline services to enhance patient management and treatment efficiency[32]. - The company has established partnerships with multiple hospitals for clinical cooperation, enhancing its product development and market competitiveness[31]. Shareholder and Stock Options - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[85]. - The company has implemented stock option incentive plans and employee stock ownership plans since 2020, with the 2024 employee stock ownership plan currently under approval[76]. - As of June 30, 2024, the company has granted a total of 12.86 million stock options under the 2020 stock option incentive plan, with 907,000 options canceled and 8.86 million options exercised[90]. - The exercise price for the stock options has been adjusted multiple times, with the latest adjustment reducing it from 8.44 RMB/share to 8.18 RMB/share[89]. - The employee stock ownership plan includes 702 employees holding a total of 9,814,200 shares, representing 2.00% of the company's total equity[94]. Compliance and Governance - The semi-annual financial report has not been audited[108]. - The company has not engaged in any major related transactions during the reporting period[109]. - The company has established detailed regulations for investment management to effectively prevent investment risks and ensure prudent decision-making[79]. - The company has improved labor systems and ensured timely salary payments while enhancing employee welfare to maintain harmonious labor relations[104]. - The company has established a transparent communication channel with shareholders through various means, including the internet and phone[103]. Environmental and Social Responsibility - The company has reduced its carbon emissions by promoting a green office environment and implementing a paperless office system[100]. - Continuous innovation and optimization of product quality are prioritized to meet customer needs and enhance market competitiveness[105]. - The company has provided product liability insurance for its products to further protect customer and consumer rights[105]. Financial Instruments and Reporting - The company recognizes financial assets and liabilities upon entering into a financial instrument contract[192]. - The company uses the effective interest method to calculate the amortized cost of financial assets and liabilities[193]. - The company categorizes financial liabilities into those measured at fair value through profit or loss and those measured at amortized cost, with the latter using the effective interest method for subsequent measurement[200]. - The company employs fair value measurement for financial assets and liabilities to provide more relevant accounting information[199]. - The company’s financial reporting adheres to the principles of fair value measurement, ensuring transparency and accuracy in financial statements[200].

天津九安医疗电子股份有限公司（以下简称"公司"）于2024年8月24日以书面方 式发出召开第六届监事会第十一次会议的通知，会议于2024年8月29日在公司会议室 以现场方式召开。本次会议由公司监事会主席姚凯先生主持，会议应参加的监事3 名，实际参加的监事3名，符合《公司法》及《公司章程》等法律法规及公司内部规 章制度的规定。会议以投票表决方式通过如下议案： 一、以 3 票同意、0 票反对、0 票弃权的表决结果审议通过了《2024 年半年度 报告及摘要》 经审核，公司监事会认为：《公司 2024 年半年度报告》全文及摘要的编制和审 核程序符合法律、行政法规及中国证监会规定，《公司 2024 年半年度报告》全文及 摘要能够真实、准确、完整地反映公司的实际情况，不存在虚假记载、误导性陈述 或者重大遗漏。 证券代码：002432 证券简称：九安医疗 公告编号：2024-055 《2024 年半年度报告全文》详见巨潮资讯网（http://www.cninfo.com.cn），《2024 年半年度报告摘要》详见《证券时报》和巨潮资讯网（http://www.cninfo.com.cn）。 天津九安医疗电子股份有限公司 二 ...

本公司及董事会全体成员保证公告内容真实、准确和完整， 并对公告中的虚假记载、误导性陈述或者重大遗漏承担连带责任。 一、募集资金基本情况 天津九安医疗电子股份有限公司（以下简称"公司"）经中国证券监督管理委员 会（以下简称"中国证监会"）《关于核准天津九安医疗电子股份有限公司非公开发行 股票的批复》（证监许可[2020]3324 号）核准，公司 2020 年度非公开发行人民币普 通股(A 股)股票 45,797,101 股，每股面值为人民币 1.00 元，发行价为每股人民币 6.90 元，募集资金总额为人民币 315,999,996.90 元，扣除与发行有关的费用 6,630,702.76 元后，实际募集资金净额为人民币 309,369,294.14 元。上述募集资金到位情况已经大 华会计师事务所（特殊普通合伙）验证并出具《天津九安医疗电子股份有限公司非 公开发行人民币普通股（A 股）的验资报告》（大华验字[2021]000141 号）。 | 项目 | 金额（人民币元） | | --- | --- | | 募集资金总额 | 315,999,996.90 | | 减：发行费用 | 6,630,702.76 | | ...

证券代码：002432 证券简称：九安医疗 公告编号：2024-054 天津九安医疗电子股份有限公司 第六届董事会第十四次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整， 并对公告中的虚假记载、误导性陈述或者重大遗漏承担连带责任。 天津九安医疗电子股份有限公司(以下简称"公司"或"本公司")于2024年8月 24日以传真和邮件方式发出召开第六届董事会第十四次会议的通知，会议于2024 年8月29日在公司会议室以现场和通讯表决相结合方式召开。本次会议由公司董 事长刘毅先生主持，会议应参加的董事6名，实际参加的董事6名，全体监事、公 司高级管理人员列席了会议，符合《公司法》及《公司章程》的规定。根据《公 司章程》规定，与会董事就会议议案进行了审议、表决，审议通过如下议案： 二、以6票同意、0票反对、0票弃权的表决结果，审议通过了《2024年半 年度募集资金存放与使用情况专项报告》 《2024年半年度募集资金存放与使用情况专项报告》详见《证券时报》和巨 潮资讯网（http://www.cninfo.com.cn）。 三、以6票同意、0票反对、0票弃权的表决结果，审议通过了《关于制定< 舆情管理制度 ...

天津九安医疗电子股份有限公司 第一条 为了提高天津九安医疗电子股份有限公司（以下简称"公司"）应 对各类舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情 对公司股价、公司商业信誉及正常生产经营活动造成的影响，切实保护投资者 合法权益，根据相关法律法规的规定和《天津九安医疗电子股份有限公司章程》 （以下简称"《公司章程》"），制定本制度。 第二条 本制度所称舆情包括： （一）报刊、电视、网络等媒体对公司进行的负面报道； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的 信息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生 较大影响的事件信息。 第三条 舆情信息的分类： （一）重大舆情：指传播范围较广，严重影响公司公众形象或正常经营活 动，使公司已经或可能遭受损失，已经或可能造成公司股票及其衍生品种交易 价格变动的负面舆情。 舆情管理制度 （二）一般舆情：指除重大舆情之外的其他舆情。 第一章 总则 第二章 舆情管理的组织体系及其工作职责 第四条 公司应对各类舆情（尤其是媒体质疑危机时）实行统一领导、统一 ...

天津九安医疗电子股份有限公司（以下简称"公司"）2024年半年度报告及报 告摘要将于2024年8月30日在巨潮资讯网（www.cninfo.com.cn）及《证券时报》 上进行公开披露。为了让广大投资者能进一步了解公司2024年半年度的经营情况， 公司将于2024年8月30日下午15:00-16:00在东方财富平台举行2024年半年度网上 业 绩 说 明 会 。 投 资 者 可 登 陆 东 方 财 富 路 演 平 台 （http://roadshow.eastmoney.com/luyan/4509794）进行参与，本次业绩说明会将采 用线上文字交流的方式。 本次说明会出席人员：公司董事长兼总经理刘毅先生，董事、副总经理王湧 先生，董事、副总经理丛明先生，独立董事孙卫军先生，董事会秘书邬彤先生， 财务经理秦菲女士（代行财务总监职责）。 为充分尊重投资者、提升交流质量，现就公司2024年半年度网上业绩说明会 提前向投资者公开征集问题。投资者可于2024年8月30日（星期五）中午12:00前 将所需了解的情况和问题一并发送至公司邮箱ir@jiuan.com。 证券代码：002432 证券简称：九安医疗 公告编号： ...

地址：北京市朝阳区光华路正大中心 2 号楼 11- 12 层 邮编：100020 电话：010-65876666 传真：010-65876666-6 北京中银律师事务所 关于天津九安医疗电子股份有限公司 2024 年员工持股计划之 法律意见书 中国·北京 二零二四年八月 法律意见书 释 义 除非本法律意见书中另有说明，下列词语之特定含义如下： 北京中银律师事务所 关于天津九安医疗电子股份有限公司 2024 年员工持股计划之 法律意见书 | 1 | 九安医疗、公司、上市 | 指 | 天津九安医疗电子股份有限公司 | | --- | --- | --- | --- | | | 公司 | | | | 2 | 本所 | 指 | 北京中银律师事务所 | | 3 | 本次员工持股计划、员 工持股计划、2024 年员 | 指 | 天津九安医疗电子股份有限公司 | | | 工持股计划 | | 年员工持股计划 2024 | | 4 | 持有人 | 指 | 参加天津九安医疗电子股份有限公 司 2024 年员工持股计划的公司员 | | | | | 工 | | 5 | 持有人会议 | 指 | 天津九安医疗电子股份有限公司 | | | ...